Potential role of oral DPP-4 inhibitors in the ADA/EASD consensus statement algorithm for achieving and maintaining tight glycaemic control in type 2 diabetes: Recommendations for oral antidiabetic agents

International Journal of Clinical Practice

Volumn 61, Issue SUPPL. 154, 2007, Pages 12-18

  Barnett, A ^a,b  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLINIDE DERIVATIVE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN; VOGLIBOSE; ANTIDIABETIC AGENT;

ADD ON THERAPY; ADVERSE OUTCOME; CARDIOVASCULAR DISEASE; CELL FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSENSUS; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SUBCUTANEOUS FAT; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; WEIGHT GAIN; WEIGHT REDUCTION; ALGORITHM; BLOOD; CONSENSUS DEVELOPMENT; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ALGORITHMS; BLOOD GLUCOSE; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 34250655417     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01440.x     Document Type: Review

References (51)

1. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 321 : 405 12.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 : 837 53. Erratum in Lancet 1999 354 : 602.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 : 854 65. Erratum in Lancet 1998 352 : 1558.
4. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 28 : 103 17.
5. Gray A, Raikou M, McGuire A et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised control trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 2000 320 : 1373 8.
6. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004 291 : 335 42.
7. Saaddine JB, Cadwell B, Gregg EW et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006 144 : 465 74.
8. Liebl A, Mata M, Eschwege E for the ODE-2 Advisory Board. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002 45 : S23 8.
9. Barnett AH. Treating to goal: challenges of current management. Eur J Endocrinol 2004 151 (Suppl. 2 T3 7, discussion T29 30.
10. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 29 : 1963 72. Erratum in Diabetes Care 2006 49 : 2816 8.
11. Ahrén B, Landin-Olsson M, Jansson PA et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinal Metab 2004 89 : 2078 84.
12. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006 60 : 1454 70.
13. DeFronzo RA, Goodman AM. Efficacy of metformin in patents with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995 333 : 541 9.
14. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996 334 : 574 9.
15. Groop L. Sulfonylureas in NIDDM. Diabetes Care 1992 15 : 737 54.
16. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004 351 : 1106 18.
17. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366 : 1279 89.
18. Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet 2005 366 : 1241 2.
19. Malaisse WJ. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2003 2 : 401 14.
20. Rosenstock J, Hassman DR, Madder RD et al. for the Repaglinide Versus Nateglinide Comparison Study Group. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004 27 : 1265 70.
21. Gerich J, Raskin P, Jean-Louis L et al. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005 28 : 2093 9.
22. Chiasson JL, Josse RG, Gomis R et al. for the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003 290 : 486 94.
23. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003 26 : 2929 40.
24. Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004 36 : 867 76.
25. Deacon CF, Ahrén B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs 2004 13 : 1091 102.
26. Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 2004 36 : 747 54.
27. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005 48 : 612 5.
28. Ahrén B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin Investig Drugs 2006 15 : 431 42.
29. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of beta-cell proliferation and inhibition of apoptosis. Endocrinology 2003 144 : 5145 8.
30. Pospisilik JA, Martin J, Doty T et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozocin-induced diabetic rats. Diabetes 2003 52 : 741 50.
31. Duttaroy A, Voelker F, Merriam K et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta-cell neogenesis and decreases apoptosis. Diabetes 2005 54 (Suppl. 1 A141 (Abstract 572-P).
32. Ahrén B, Gomis R, Standl E et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004 27 : 2874 80.
33. Deacon CF. MK-431 (Merck). Curr Opin Investig Drugs 2005 6 : 419 26.
34. Mari A, Sallas WM, He YL et al. Vildagliptin, a dipetidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005 90 : 4888 94.
35. Herman GA, Bergman A, Liu F et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006 46 : 876 86.
36. Miller S, St Onge EL. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother 2006 40 : 1336 43.
37. Aschner P, Kipnes MS, Lunceford JK et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006 29 : 2632 7.
38. Charbonnel B, Karasik A, Liu J et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006 29 : 2638 43.
39. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007 30 : 217 23.
40. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007 39 : 218 23.
41. Dejager S, Lebeaut A, Couturier A, Schweizer A. Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). Diabetes 2006 55 (Suppl. 1 A29 (Abstract 120-OR).
42. Nathwani A. The use of vildagliptin for treatment of patients with type 2 diabetes mellitus. American Diabetes Association - 66th Scientific Sessions. Washington, DC, 2006, 9-13 June (meeting abstract).
43. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007 30 : 890 5.
44. Rosenstock J, Baron MA, Camisasca R-P, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007 9 : 175 85.
45. Fonseca V, Dejager S, Albrecht D et al. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM). Diabetes 2006 55 (Suppl. 1 A111 (Abstract 467-P).
46. Raz I, Hanefeld M, Xu L et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006 49 : 2564 71.
47. Rosenstock J, Brazg R, Andryuk PJ et al. Addition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM). Diabetes 2006 55 (Suppl. 1 A132 3.
48. Stein P. Sitagliptin: a novel dipeptidyl peptidase-4 inhibitor for the treatment of patients with type 2 diabetes. American Diabetes Association - 66th Scientific Sessions. Washington, DC, 2006, 9-13 June (meeting abstract).
49. Jago C. American Diabetes Association - 66th scientific sessions. 9-13 June 2006, Washington, DC, USA, I Drugs 2006 9 : 538 41.
50. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000 283 : 1695 702. Erratum in JAMA 2000 284 : 1384.
51. Bailey CJ, Bagdonas A, Rubes J et al. Rosiglitazone/metformin fixed dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther 2005 27 : 1548 61.